title: Cell cycle inhibitors make progress.
authors.forename: Vicki
authors.initials: V
authors.lastname: Brower
mesh_terms: D000631:Aminopyridines / Q000494:pharmacology* / Q000627:therapeutic use*; D000970:Antineoplastic Agents / Q000494:pharmacology* / Q000627:therapeutic use*; D001562:Benzimidazoles / Q000494:pharmacology* / Q000627:therapeutic use*; D001943:Breast Neoplasms / Q000188:drug therapy* / Q000378:metabolism; D002453:Cell Cycle / Q000187:drug effects*; D017321:Clinical Trials, Phase I as Topic; D051358:Cyclin-Dependent Kinase 4 / Q000037:antagonists & inhibitors*; D051361:Cyclin-Dependent Kinase 6 / Q000037:antagonists & inhibitors*; D005260:Female; D006801:Humans; D010879:Piperazines / Q000494:pharmacology* / Q000627:therapeutic use*; D011518:Proto-Oncogene Proteins / Q000187:drug effects; D016283:Proto-Oncogene Proteins p21(ras); D011687:Purines / Q000494:pharmacology / Q000627:therapeutic use; D011725:Pyridines / Q000494:pharmacology* / Q000627:therapeutic use*; D016032:Randomized Controlled Trials as Topic; D011960:Receptors, Estrogen / Q000378:metabolism; D018631:ras Proteins / Q000187:drug effects
chemical_list: D000631:Aminopyridines; D000970:Antineoplastic Agents; D001562:Benzimidazoles; C117307:KRAS protein, human; D010879:Piperazines; D011518:Proto-Oncogene Proteins; D011687:Purines; D011725:Pyridines; D011960:Receptors, Estrogen; C000590451:abemaciclib; C495900:CDK4 protein, human; C495911:CDK6 protein, human; D051358:Cyclin-Dependent Kinase 4; D051361:Cyclin-Dependent Kinase 6; D016283:Proto-Oncogene Proteins p21(ras); D018631:ras Proteins; C500026:palbociclib; C000589651:ribociclib